Mylan Investors Push Back At Bid To Toss EpiPen Claims

By Dean Seal (September 6, 2018, 4:29 PM EDT) -- Investors in Mylan NV fired back at what they called a scattershot motion to dismiss their amended claims about alleged anti-competitive behavior involving the drugmaker's EpiPen epinephrine auto-injector, saying their latest allegations are "well-pleaded and damning."...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!